Audentes Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. BOLD, a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in November:  

• Credit Suisse 27th Annual Healthcare Conference
  Natalie Holles, President and Chief Operating Officer
  Format: 1x1 Investor Meetings
  Wednesday, November 14, 2018
  Scottsdale, Arizona
• Evercore ISI HealthConX Conference
  Matthew R. Patterson, Chairman and Chief Executive Officer
  Format: Fireside Chat
  Tuesday, November 27, 2018, 10:35am EST
  Boston, Massachusetts
• Piper Jaffray 30th Annual Healthcare Conference
  Matthew R. Patterson, Chairman and Chief Executive Officer
  Format: Fireside Chat
  Wednesday, November 28, 2018, 11:30am EST
  New York, New York
• Barclays Gene Editing & Gene Therapy Summit
  Matthew R. Patterson, Chairman and Chief Executive Officer
  Format: Corporate Presentation
  Thursday, November 29, 2018, 10:15am EST
  New York, New York

To access live webcasts of the fireside chats and presentation please visit the Events & Presentations page within the Investors + Media section of the Audentes website.  Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. 

About Audentes Therapeutics, Inc.
Audentes Therapeutics BOLD is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases.  We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome.  We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com 

Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com

SOURCE Audentes Therapeutics, Inc.